What we found on the web about Gleevec
Imatinib - Wikipedia, the free encyclopedia
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec or Glivec (Europe / Australia) as its mesylate salt, imatinib mesilate ...
Philadelphia chromosome - Wikipedia, the free encyclopedia
In the late 1990s, STI-571 (imatinib, Gleevec/Glivec) was identified by Novartis pharmaceuticals in high-throughput screens for tyrosine kinase inhibitors.
GLEEVEC® Safety Information | My CML Circle™
GLEEVEC® (imatinib mesylate) tablets are indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in ...
Gleevec, Imatinib Mesylate, Glivec - Chemotherapy Drugs, Chemo Drug ...
Gleevec is the trade name for Imatinib Mesylate. Glivec and STI-571 are other names for Imatinib Mesylate. Gleevec is a targeted therapy. It is classified as a signal transduction ...
Gleevec
January 5, 2007. An open letter from Novartis regarding the Glivec legal challenge in India. Word (World) to Novartis: drop lawsuit over Indian patent law.
Unofficial Gleevec Site
sti571, sti-571, Gleevec, Glivec, leukemia, chronic myelogenous leukemia, cml, gist, c-kit, gastrointestinal stromal tumor, leiomyosarcoma, cancer, tyrosine kinase inhibitor ...
Imatinib - Wikipedia, the free encyclopedia
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec or Glivec (Europe / Australia) as its mesylate salt, imatinib mesilate ...
Gleevec (Imatinib Mesylate) Drug Information: Uses, Side Effects, Drug ...
Learn about the prescription medication Gleevec (Imatinib Mesylate), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.
Gleevec Lawsuit Heart Damage Side Effects Lawyer
Cancer drug gleevec has been linked to heart damage and serious cardiac injuries, Free gleevec lawsuit consultation by qualified drug side effects lawyer.
Gleevec - definition of Gleevec in the Medical dictionary - by the ...
Gleevec. Imatinib mesylate Oncology An anticancer monoclonal antibody that blocks signaling of defective proteins, which may be effective against CML, brain tumors, GI and lung CAs
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Gleevec

Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It was originally coded during development as CGP57148B or STI-571 (these terms are used in early preclinical publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Gleevec
Results Differentiate STA-9090 In Hsp90 Inhibitor Class And Show ...
Medical News Today
Along with work presented by Dr. Shapiro's lab, we and our collaborators have shown broad activity of STA-9090 against multiple cancer types, including both cancers that are sensitive to kinase inhibitors, such as Gleevec and Sutent, and ca...
Pipeline Insight - Hematological Malignancies Companies target niche ...
PR Inside
... drugs are in late-phase studies and are forecast to achieve peak sales of $3.5 billion in 2018. Drug developers are keen to replicate the success of the two blockbusters: Biogen Idec/Genentech/Roche´s Rituxan (rituximab) and Novartis´s...
The Next Cancer Bestseller?
Forbes
Novartis hit a $3.7 billion (annual sales) home run with its leukemia drug Gleevec, launched in 2001. Now it hopes Afinitor will be its next cancer bestseller, says David Epstein, who leads Novartis' cancer drug business. It was approved in...
Once Again: Patents Do Not Equal Innovation
Tech Dirt
I think leukemia patients would notice if there were fewer medicines like Gleevec around. I also think people would raise a stink about the lack of research going into green technology, especially nowadays. Not all ...
Novartis posts 14 percent drop in Q1 profit
AOL
Analysts at Zuercher Kantonalbank gave Novartis a "slightly positive rating." They said the pharma division was showing strength again but that its sales of blood-pressure drug Diovan and its best-selling anticancer drug Glivec — known as G...
Study: Re-engineered Gleevec Reduces Heart Risks
Phramalive.com
Using the PharmaLive Search Tool, you can query current and historical information on thousands of pharma companies and products, and with PharmaLive NewsPass, you can view all results returned from your search. Searching information is sim...
Novartis Profit Beats Estimates; Shares Rise (Update1)
Bloomberg
Increased revenue from the hypertension drug Diovan and the cancer treatment Gleevec countered some of the effect from currency shifts. Chief Executive Officer Daniel Vasella confirmed the company’s forecast and said 2009 profit may fall be...
O’Neal: Fawcett’s had ‘terrible time’ in past year
MSNBC
And she said, ‘Then stop the Gleevec — the medicine that I take for my leukemia.’ So she made a joke: ‘Stop the Gleevec.’ ” O’Neal’s interview with Vieira airs on TODAY Wednesday and Thursday. In addition, O’Neal and close family ...
Gleevec Approved for Use After Cancer Surgery
MedicineNet.com
Minorities to See Rise in U.S. Cancer Cases Young Women's Breast Tissue Offers Clues to Cancer Gene Alteration May Affect Breast Cancer Therapy Acrylamide Doesn't Raise Lung Cancer Risk Well Water Might Raise Bladder Cancer Risk Want More N...
Predicting Patient Response To Gleevec In Gastrointestinal Stromal ...
Science Daily
ScienceDaily (Apr. 29, 2009) — Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover...